A National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer (PLC)

The primary objective of the NCI-CLARITY study is to establish a biospecimen repository for genomic, genetic and epigenetic analysis to study the biology of primary liver cancer (PLC) development and progression. Secondary objectives include predicting overall and progression-free survival following immunotherapy. In the retrospective phase, anonymous archival tissue from PLC patients was obtained from five participating sites. Whole exome and transcriptome sequencing was generated and used to predict overall survival in response to immunotherapy.

NCI-CLARITY研究的首要目标是建立一座生物样本库，用于开展基因组学、遗传学及表观遗传学分析，以探究原发性肝癌（primary liver cancer, PLC）发生与进展的生物学机制。其次要目标包括预测免疫治疗后的总生存期与无进展生存期。在回顾性研究阶段，本研究从5家参与机构获取了原发性肝癌患者的匿名存档组织样本，并通过全外显子组测序与转录组测序生成测序数据，以此预测免疫治疗响应相关的总生存期。